A clinical trial update dated October 15, 2026 reports a change in status for a study involving degarelix. The trial, registered as NCT03689699 and titled "Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)," is now listed as completed.
MAGIC-8 is a Phase 1/2 study. According to the registry record, its current status has moved to completed as of the date noted above. The listing does not include results data in this update.
This brief reflects only the status change recorded in the trial registry. No outcome data, efficacy claims, or safety findings are included in this update. The record does not specify additional details beyond the trial's title, phase, and completion status.
Degarelix remains an approved compound, and this trial update concerns its investigational use in combination with nivolumab and BMS-986253 in this study context. Readers interested in the trial's eventual results should monitor the registry listing directly for future updates, as this brief does not contain outcome information.
For more background on this compound, see the linked compound overview.